A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles
Erişim
info:eu-repo/semantics/closedAccessTarih
2017Yazar
Şekerdağ, EmineLüle, Sevda
Bozdağ Pehlivan, Sibel
Öztürk, Naile
Kara, Aslı
Kaffashi, Abbas
Vural, İmran
Işıkay, İlkay
Yavuz, Burçin
Karlı Oğuz, Hatice Kader
Söylemezoğlu, Figen
Gürsoy Özdemir, Yasemin
Mut, Melike
Üst veri
Tüm öğe kaydını gösterKünye
Sekerdag, E., Lüle, S., Pehlivan, S. B., Öztürk, N., Kara, A., Kaffashi, A., ... & Söylemezoğlu, F. (2017). A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles. Journal of Controlled Release, 261, 187-198.Özet
New drug delivery systems are highly needed in research and clinical area to effectively treat gliomas by reaching a high antineoplastic drug concentration at the target site without damaging healthy tissues. Intranasal (IN) administration, an alternative route for non-invasive drug delivery to the brain, bypasses the blood-brainbarrier (BBB) and eliminates systemic side effects. This study evaluated the antitumor efficacy of farnesylthiosalicylic acid (FTA) loaded (lipid-cationic) lipid-PEG-PLGA hybrid nanoparticles (HNPs) after IN application in rats. FTA loaded HNPs were prepared, characterized and evaluated for cytotoxicity. Rat glioma 2 (RG2) cells were implanted unilaterally into the right striatum of female Wistar rats. 10 days later, glioma bearing rats received either no treatment, or 5 repeated doses of 500 mu M freshly prepared FTA loaded HNPs via IN or intravenous (IV) application. Pre-treatment and post-treatment tumor sizes were determined with MRI. After a treatment period of 5 days, IN applied FTA loaded HNPs achieved a significant decrease of 55.7% in tumor area, equal to IV applied FTA loaded HNPs. Herewith, we showed the potential utility of IN application of FTA loaded HNPs as a non-invasive approach in glioblastoma treatment.